



Hyperthermia-based Anticancer Treatments

Guest Editors:

Dr. Nicolaas A.P. Franken

Dr. Arlene L. Oei

Dr. Johannes Crezee

Deadline for manuscript
submissions:

closed (31 March 2020)

Message from the Guest Editors

Hyperthermia—an adjuvant anti-cancer treatment using temperatures exceeding the physiologically optimal level—affects cells and tissues in various ways. For several decades it has been successfully applied for treatment of many tumour types, including recurrent breast cancer, cervical carcinoma, head & neck cancer and melanoma. Hyperthermia affects multiple intracellular processes, DNA repair pathways, as well as systemic immune responses. Furthermore, it can target cancer cells in hypoxic and nutrient-deprived tumour areas where ionising radiation and chemotherapy are least effective. Hyperthermia can also modify factors that are essential for tumour survival and growth. Thus, the effects of hyperthermia are multifactorial. Hyperthermia is a clinically proven successful adjuvant treatment. As such in this Special Issue of *Cancers* we aim to increase awareness of the benefits of hyperthermia to a broader audience and to discuss all novel preclinical and clinical aspects of hyperthermia-based anticancer treatments and welcome contributions to this theme.





cancers



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
X@Cancers_MDPI